IRIS - Res&Arch Institutional Research Information System - Research & Archive

CIPRIANI, Sabrina
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.743
EU - Europa 1.171
AS - Asia 520
SA - Sud America 1
Totale 3.435
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.737
IE - Irlanda 318
IT - Italia 254
UA - Ucraina 152
VN - Vietnam 134
SG - Singapore 127
SE - Svezia 114
HK - Hong Kong 112
CN - Cina 87
FI - Finlandia 75
RU - Federazione Russa 67
FR - Francia 47
DE - Germania 45
TR - Turchia 31
GB - Regno Unito 27
KR - Corea 16
CH - Svizzera 15
RO - Romania 14
AT - Austria 8
BE - Belgio 8
CZ - Repubblica Ceca 8
NL - Olanda 8
PL - Polonia 6
LB - Libano 5
UZ - Uzbekistan 5
GR - Grecia 4
CA - Canada 3
MX - Messico 3
TW - Taiwan 2
CL - Cile 1
JP - Giappone 1
NO - Norvegia 1
Totale 3.435
Salva come PNG Salva come JPEG
Città #
Chandler 396
Dublin 317
San Mateo 193
Dong Ket 134
Hong Kong 112
Boardman 101
Perugia 101
Ann Arbor 90
Altamura 88
Singapore 85
Medford 78
Princeton 78
Jacksonville 69
Lawrence 69
Wilmington 64
Andover 63
Beijing 48
Izmir 31
Des Moines 27
Saint Petersburg 27
Dearborn 21
Seoul 16
Timisoara 14
Santa Clara 13
Helsinki 12
San Paolo di Civitate 12
Houston 11
Los Angeles 11
Norwalk 11
Redmond 11
Ashburn 10
Falls Church 10
Woodbridge 9
Brussels 8
Den Haag 8
Redwood City 7
Olomouc 6
Dallas 5
London 5
Vienna 5
Chicago 4
Giugliano In Campania 3
Moscow 3
Chiyayi County 2
Kiev 2
Lappeenranta 2
Lausanne 2
Nanjing 2
Naples 2
Ottawa 2
Rome 2
Rovato 2
Shanghai 2
Stenico 2
Alba 1
Anguillara Sabazia 1
Baotou 1
Bisaccia 1
Bologna 1
Cork 1
Deruta 1
Edinburgh 1
Figline Valdarno 1
Foggia 1
Foligno 1
Frankfurt Am Main 1
Fremont 1
Hanover 1
Kunming 1
Marseille 1
Prague 1
Salerno 1
San Diego 1
Simi Valley 1
Tappahannock 1
Terni 1
Tokyo 1
Toronto 1
Turin 1
Vico Equense 1
Totale 2.434
Salva come PNG Salva come JPEG
Nome #
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 86
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 85
Anti-HIV Protease Inhibitors Interact With NSAIDs and Exacerbate Small Intestine Enteropathy Induced by NSAIDs 85
BAR502, a Dual FXR and GPBAR1 Agonist, Reverses Steatosis and Fibrosis in Rodent Model of NASH By Modulating Authophagic Genes 84
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 83
The bile acid receptor GPBAR1 regulates the M1/M2 phenotype of intestinal macrophages and activation of gpbar1 rescues mice from murine colitis 82
The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines 80
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 71
BAR 501, a Novel GPBAR1 Ligand, Reverses Intestinal and Liver Inflammatory Models Demonstrating That GPBAR1 Is an Essential Modulator of Innate Immunity in Entero-Hepatic Tissues 71
BAR501, A SELECTIVE GPBAR1 AGONIST, PROMOTES ADIPOSE TISSUE BROWNING AND AUTOPHAGY AND IMPROVES LIPID METABOLISM AND STEATO-HEPATITIS IN MICE FEED A HIGH FAT DIET 69
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 67
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 63
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 61
A Comprehensive Analysis of Small Heterodimer Partner (SHP) Target Genes in Hepatic Stellate Cells and the Discovery of a New Class of SHP Agonists That Reduces Liver Fibrosis 61
BAR130, A HYODEOXYCHOLIC ACID DERIVATIVE AS THE FIRST EXAMPLE OF DUAL LXR alpha/GPBAR1 AGONIST 59
Leflunomide protects against dyslipidemia development induced by ritonavir in mice 55
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 54
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 54
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study 54
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 53
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 53
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 52
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 52
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 52
Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa 52
Genetic Ablation and Pharmacological Blockade of CCR5 by the anti-HIV Small Molecule Inhibitor Maraviroc Inhibits Leukocyte Trafficking and Protects Against Mucosal Inflammation in Murine Models Colitis 52
DISCOVERY OF BAR704, A POTENT AND SELECTIVE FXR AGONIST, THAT PROTECTS AGAINST LIVER FIBROSIS 52
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 51
BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis 51
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 50
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases 50
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 50
A Platelet's Guide to Synovitis 47
Microencapsulated G3C hybridoma cell graft delays the onset of spontaneous diabetes in NOD mice by an expansion of Gitr+ Treg cells 47
The HIV Matrix Protein p17 promotes the Activation of human hepatic stellate cells through interactions with CXCR2 and Syndecan-2 46
Metabolic variability of a multispecies probiotic preparation impacts on the anti-inflammatory activity 46
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 45
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 44
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 43
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 43
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 43
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 42
Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands 41
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 41
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 40
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 40
Cystathionine gamma-lyase, a H2S-generating enzyme, is a GPBAR1-regulated gene and contributes to vasodilation caused by secondary bile acids 40
Nanotraps with biomimetic surface as decoys for chemokines 40
Pregnane-X-receptor mediates the anti-inflammatoryactivities of rifaximin on detoxification pathways in intestinal epithelialcells. 39
Impaired Itching Perception in Murine Models of Cholestasis Is Supported by Dysregulation of GPBAR1 Signaling 39
Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice 39
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 37
GPBAR1 (TGR5) LIGATION PROTECTS AGAINST COLITIS DEVELOPMENT BY REGULATING LEUKOCYTE TRAFFINKING AND PROMOTING A IL-10 DEPENDENT SHIFT IN THE M1/M2 PHENOTYPE 37
VARIABILITY IN INDUSTRIAL PRODUCTION AFFECTS PROBIOTICS ACTIVITY: IDENTIFICATION OF BATCHES OF PROBIOTIC VSL#3 THAT INCREASES INTESTINAL PERMEABILITY AND WORSENS COLITIS IN RODENTS 35
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 35
Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. 34
Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1 33
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 32
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 32
Decoding the role of the nuclear receptor SHP in regulating hepatic stellate cells and liver fibrogenesis 32
The HIV matrix protein p17 induces hepatic lipid accumulation via modulation of nuclear receptor transcriptoma 31
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 30
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. 30
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 29
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 29
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 28
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 27
Reciprocal Regulation of TLRS and Nuclear Receptors: IRF-7 Dependent Regulation of FXR Mediates Counter-Regulatory Effects of TLR-9 in Colitis 27
Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). 27
Preterm Birth, Low Gestational Age, Low Birth Weight, Parity, and Other Determinants of Breech Presentation: Results from a Large Retrospective Population-Based Study 27
Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment 26
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 25
Mechanistic role of p38 MAPK in gastric cancer dissemination in a rodent model peritoneal metastasis. 25
Targeting Bile Acid Receptors: Discovery of a Potent and Selective Farnesoid X Receptor Agonist as a New Lead in the Pharmacological Approach to Liver Diseases 25
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 25
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 24
Highly specific blockade of CCR5 inhibits leukocyte trafficking and reduces mucosal inflammation in murine colitis 24
Hyodeoxycholic acid derivatives as liver X receptor α and G-protein-coupled bile acid receptor agonists 21
Dietary habits and semen parameters: a systematic narrative review 17
Totale 3.603
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.785
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.785
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020216 0 0 0 3 33 26 48 8 41 49 5 3
2020/2021564 6 29 20 47 179 21 25 8 32 16 32 149
2021/2022676 7 132 2 34 31 7 14 223 8 32 85 101
2022/20231.223 81 243 7 124 115 116 0 62 431 1 32 11
2023/2024394 31 52 25 3 2 2 97 13 10 20 84 55
2024/2025153 16 88 47 2 0 0 0 0 0 0 0 0
Totale 3.603